Zimmer Biomet Holdings, Inc. (ZBH) Gross Margin: 70.03%
Is Zimmer Biomet Holdings, Inc.’s gross margin high or low?
Zimmer Biomet Holdings, Inc.'s gross margin of 70.03% is in line with its 5-year average of 69.55%, near the high end of its 5-year range (61.62%–71.82%).
As of Saturday, June 20, 2026. 5.24% above its 12-month average of 66.54%.
ZBH Gross Margin Chart
ZBH Average Gross Margin Chart
ZBH Current vs Average Gross Margin Chart
ZBH Gross Margin Metrics
GROSS MARGIN
70.03%
GROSS MARGIN AVG TTM
66.54%
GROSS MARGIN AVG 3Y
68.95%
GROSS MARGIN AVG 5Y
69.55%
GROSS MARGIN AVG 10Y
70.19%
GROSS MARGIN AVG 15Y
72.11%
GROSS MARGIN AVG 20Y
73.30%
CURRENT VS TTM AVG
+5.24%
CURRENT VS 3Y AVG
+1.57%
CURRENT VS 5Y AVG
+0.69%
CURRENT VS 10Y AVG
-0.22%
CURRENT VS 15Y AVG
-2.89%
CURRENT VS 20Y AVG
-4.46%
ZBH Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. (ZBH) | $17.02B | 70.03% | 66.54% | 68.95% | 69.55% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 52.82% | 58.14% | 57.33% | 59.28% |
| DaVita Inc. (DVA)vs › | $13.34B | 31.10% | 29.95% | 30.17% | 30.48% |
| Medpace Holdings, Inc. (MEDP)vs › | $13.14B | 29.07% | 30.59% | 29.65% | 29.57% |
| Solventum Corporation (SOLV)vs › | $13.06B | 53.67% | 54.56% | 56.03% | 57.27% |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 27.79% | 27.30% | 28.39% | 31.16% |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 67.68% | 69.16% | 69.73% | 70.75% |
| The Cooper Companies, Inc. (COO)vs › | $12.85B | 64.37% | 63.66% | 64.40% | 64.61% |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 86.58% | 88.58% | 89.63% | 90.66% |
| Revvity, Inc. (RVTY)vs › | $11.16B | 51.44% | 50.55% | 50.58% | 52.43% |
Gross Margin Analysis
Gross Margin
70.0%
(Revenue - COGS) / Revenue
Zimmer Biomet Holdings, Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zimmer Biomet Holdings, Inc. Gross Margin FAQ
- What is the gross margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The gross margin for ZBH stock is 70.03%.
- Is Zimmer Biomet Holdings, Inc.'s gross margin high or low?
- Zimmer Biomet Holdings, Inc.'s gross margin of 70.03% is in line with its 5-year average of 69.55%, near the high end of its 5-year range (61.62%–71.82%).
- What is the TTM average gross margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The TTM average gross margin for ZBH stock is 66.54%.
- What is the 3Y average gross margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 3Y average gross margin for ZBH stock is 68.95%.
- What is the 5Y average gross margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 5Y average gross margin for ZBH stock is 69.55%.
- What is the 10Y average gross margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 10Y average gross margin for ZBH stock is 70.19%.
- What is the 15Y average gross margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 15Y average gross margin for ZBH stock is 72.11%.
- What is the 20Y average gross margin for Zimmer Biomet Holdings, Inc. (ZBH)?
- The 20Y average gross margin for ZBH stock is 73.30%.
Zimmer Biomet Holdings, Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 61.62% |
| 2024-12-31 | 71.46% |
| 2023-12-31 | 71.82% |
| 2022-12-31 | 70.90% |
| 2021-12-31 | 71.29% |
| 2020-12-31 | 70.23% |
| 2019-12-31 | 71.78% |
| 2018-12-31 | 71.36% |
| 2017-12-31 | 72.67% |
| 2016-12-31 | 68.94% |
| 2015-12-31 | 69.98% |
| 2014-12-31 | 73.41% |
| 2013-12-31 | 72.18% |
| 2012-12-31 | 74.84% |
| 2011-12-31 | 74.80% |
| 2010-12-31 | 76.02% |
| 2009-12-31 | 75.81% |
| 2008-12-31 | 75.80% |
| 2007-12-31 | 77.53% |
| 2006-12-31 | 77.68% |
| 2005-12-31 | 77.50% |
| 2004-12-31 | 73.84% |
| 2003-12-31 | 72.85% |
| 2002-12-31 | 74.88% |
| 2001-12-31 | 72.35% |
| 2000-12-31 | 72.04% |
| 1999-12-31 | 71.35% |
| 1998-12-31 | 69.22% |
Related Metrics
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. (ZBH), along with its global subsidiaries, operates as a leading player in the musculoskeletal healthcare sector. The company extends its reach across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. ZBH is responsible for the design, manufacturing, and marketing of a wide array of orthopedic reconstructive solutions, including prominent knee and hip replacement systems. Their offerings also encompass Specialized Enabling Technologies (S.E.T.) products, which cover areas such as sports medicine, biologics, foot and ankle care, extremity treatments, and trauma management. Furthermore, the company provides medical devices and surgical instruments specifically for spinal conditions, alongside products for facial and cranial reconstruction. A unique part of their portfolio includes systems designed to stabilize and fixate chest bones, facilitating recovery or reconstruction following open-heart surgery, traumatic injuries, or congenital chest deformities. The company's product lines also feature a comprehensive range of dental solutions, such as reconstructive implants, prosthetics, and regenerative materials. Additionally, they are involved in robotic surgical systems, general surgical instruments, and bone cements. These advanced products and solutions are primarily utilized to address conditions in patients suffering from disorders or injuries affecting bones, joints, and their associated soft tissues. Zimmer Biomet caters to a broad clientele, including orthopedic, neuro-, and oral surgeons, dentists, hospitals, independent distributors, healthcare suppliers, and various other medical specialists. Their network further encompasses agents, healthcare purchasing organizations, and group buying alliances. Originally established in 1927, the enterprise was initially known as Zimmer Holdings, Inc., before rebranding as Zimmer Biomet Holdings, Inc. in June 2015. Its corporate headquarters are situated in Warsaw, Indiana.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ivan Tornos